RecruitingObesityOverweightDiabetes Mellitus, Type 2

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Eligible age

18–99 yrs

Accepts

All genders

Locations

13 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).

Sponsor: Amgen

You may qualify if…

✓ Signed informed consent form (ICF) indicating compliance with the requirements and restrictions listed in the ICF and this protocol.
✓ Participants completing Study 20210184 must meet the following criteria:
✓ Completed the Week 72 visit in Study 20210184.
✓ Did not permanently discontinue the investigational product in the parent trial (20210184).
✓ Randomized within 7 days of week 72 visit in the parent trial.
✓ Participants must use protocol-specified contraception during treatment and for 16 weeks after the last dose of trial intervention.

You may not qualify if…

✕ Planned (during the trial) surgical, endoscopic, or device-based treatment for obesity.
✕ Body mass index (BMI) ≤ 18.5 kilograms per meter square (kg/m\^2).
✕ Participant has known sensitivity to any of the products or components to be administered during dosing.
✕ History of ischemic optic neuropathy.
✕ Any malignancy diagnosed during the parent trial, except for the following treated with curative intent:
✕ Nonmelanoma skin cancers
✕ Breast ductal carcinoma in situ
✕ Cervical carcinoma in situ